Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Operating Expenses (2022 - 2025)

Stoke Therapeutics has reported Operating Expenses over the past 4 years, most recently at $215.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 288.7% year-over-year to $215.2 million; the TTM value through Dec 2025 reached $263.5 million, up 2226.01%, while the annual FY2025 figure was $205.0 million, 1754.51% up from the prior year.
  • Operating Expenses for Q4 2025 was $215.2 million at Stoke Therapeutics, up from $53.7 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $215.2 million in Q4 2025 and troughed at -$114.1 million in Q4 2024.
  • A 4-year average of $30.7 million and a median of $30.5 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: plummeted 452.14% in 2024 and later soared 288.7% in 2025.
  • Year by year, Operating Expenses stood at $30.4 million in 2022, then rose by 6.39% to $32.4 million in 2023, then plummeted by 452.14% to -$114.1 million in 2024, then soared by 288.7% to $215.2 million in 2025.
  • Business Quant data shows Operating Expenses for STOK at $215.2 million in Q4 2025, $53.7 million in Q3 2025, and -$3.8 million in Q2 2025.